What is OGN's 12-month price target and RQD AI Jury consensus?

OGN's 12-month base price target is $14.57 (range $11.33 to $17.19), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / OGN

XENE (37) AMLX (39) IRON (54) ACAD (49) ⌘ Pro Terminal →

Organon & Co. (OGN) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell OGN stock right now?

Organon & Co. (OGN) currently earns a Roarable Rating of B- (Buy — BUY) with 70/100 RQD Confidence. High-quality cash engine (53.3% gross margin, 25% return on capital) with steady institutional support.

$13.82 -0.14% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.85

Organon & Co. (OGN) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (53.3% gross margin, 25% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B- • BUY Cap $3.63B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OGN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Organon & Co. (NYSE: OGN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $13.82 (-0.14% 1D, market cap $3.63B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, OGN ranks #76 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OGN compare to XENE and AMLX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OGN carries a Roarable B- (70/100 RQD), trailing P/E of 19.4x, gross margin of 53.3%, and ROIC of 24.9%. By comparison, XENE (Xenon Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B) and AMLX (Amylyx Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OGN?

▼

Per OGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001821825), Organon & Co. generated $6.22B in revenue (-2.9% YoY), $187.0M in net income, and $538.0M in free cash flow against $12.87B in total assets and $8.63B in total debt. Key quantitative strengths: Strong cash generator (53.3% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $13.85 (+0.21%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 8.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 70/100 (B-) historically ranked in the Top 15% of excess returns over the next 90 days (+6.6% avg 90D alpha vs SPY • 68.1% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE+5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OGN)Realized 20D OHLCV Swing Band: ±1.8%

Deterministic 5-Pillar Attribution (70/100 Composite)

🔍 WHY OGN SCORES 70/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 8.7% FCF Margin ($538.0M FCF) & 53.3% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+16/20 pts (23% of score)

20D Institutional Volume Accumulation (±1.8% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit9/20 pts (-11 pt drag)

Macro rate sensitivity & RSI-14 (64.5) create a -11 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$13.77-0.1% Next Q

Q2 (-2Q)

Grade C+$13.76-0.1% Next Q

Q3 (-1Q)

Grade B-$13.75+0.5% Next Q

Current

Grade B-$13.82+6.6% Hist 90D α

Trajectory: C+ (62) → B- (70)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the OGN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 70/100 (B-) score, OGN faces multiple-compression risk if 19.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($13.74) or 200D SMA ($11.57) invalidates the momentum regime and cuts Target Base ($14.57) toward Bear Floor ($11.33).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “OGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 70%NO 30%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

64.530 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

6 / 99-Pt Accounting

52-WEEK LASER RANGE99% OF RANGE

L: $6$13.82H: $14

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (53.3% gross margin and healthy balance-sheet cushion).

Factor Grade: ARQD 18 / 20

2. Big Money & Insiders● BUYING

Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: B+RQD 32 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on OGN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (90)

24.9% ROIC with 53.3% gross margin and 14.83% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (55)

Altman-Z 4.20 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (68)

32/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like OGN

✓Strong cash generator (53.3% gross margin)—profits are backed by real money, not accounting tricks.
✓Big institutional funds and options desks are actively positioning on the bullish side.
✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (OGN Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +4.22%⚡ TESTING RESISTANCE

2026-11-03O $13.81H $13.84L $13.81C $13.82VOL 1.85M

RES: $13.86SUP: $13.76SMA50: $13.74SMA200: $11.57

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OGN Butterfly Map → + Track OGN →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

12.8%/yr Implied 5Y Growth

vs. -2.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on OGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OGN)

Health Care Rank #76 of 1015 ⚔️ XENE vs OGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OGN vs. XENE, AMLX, IRON, ACAD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Organon & Co. (OGN) ranks #76 by composite RQD confidence (70/100, grade B-) and #188 by equity capitalization ($3.63B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. OGN currently leads its immediate peer cohort in composite quantitative strength at 70/100 (B-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OGN ACTIVE Organon & Co.	B-	70/100	19.4x	53.3%	24.9%	-0.14%	$3.63B	Benchmark Subject
XENE Xenon Pharmaceuticals Inc.	D-	37/100	—	—	-35.0%	+0.56%	$3.62B	/xene-vs-ogn →
AMLX Amylyx Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	-2.84%	$3.62B	/amlx-vs-ogn →
IRON Disc Medicine Inc.	D+	54/100	—	—	-27.5%	-2.75%	$3.59B	/iron-vs-ogn →
ACAD ACADIA Pharmaceuticals Inc.	D	49/100	9.1x	91.7%	7.9%	-0.58%	$3.55B	/acad-vs-ogn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001821825 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Organon & Co. (OGN) reported GAAP revenue of $6.22B (-2.9% vs. FY2024 revenue of $6.40B , and -0.8% cumulative change since FY2023) , GAAP net income of $187.0M, operating cash flow of $700.0M, and free cash flow of $538.0M (-29.6% YoY). On the balance sheet, OGN closed FY2025 with $12.87B in total assets against $8.63B in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$6.22B	$187.0M	$700.0M	$538.0M	$12.87B	$8.63B
FY2024 (FY)	2024-12-31	$6.40B	$864.0M	$939.0M	$764.0M	$13.10B	$8.86B
FY2023 (FY)	2023-12-31	$6.26B	$1.02B	$799.0M	$799.0M	—	—

3. OGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does OGN compare to XENE and AMLX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for OGN?

Where is OGN trading relative to its 50-day, 200-day, and 52-week technical levels?

OGN last traded at $13.82 (-0.14% on volume of 2,147,472 shares), positioning the stock +0.58% above its 50-day simple moving average ($13.74) and +19.45% above its 200-day simple moving average ($11.57). Across its 52-week range of $5.69 to $13.84, OGN sits at the 99.8% percentile with a 14-day RSI of 64.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±1.8% ($13.57 to $14.07).

Direct Sub-Reports: OGN RQD Cockpit OGN 12M Forecast OGN Earnings & Move OGN Dividends & DRIP OGN Insiders & 13F OGN Whale Options OGN Profit Sankey OGN News & Why

ROARABLE RATING BRIEF • RQD 70/100 (B-) ✓ SEC XBRL & RQD VERIFIED

OGN — Organon & Co.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Organon & Co. (OGN) earns a live Roarable RQD composite score of 70/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $13.82 (-0.14% 1D, market capitalization $3.63B).

Fundamental Cash Engine (18/20): Anchored by return on invested capital (ROIC) of 24.9%, gross margin of 53.3%, operating margin of —, and free cash flow yield of 14.83%.
Whale 13F & Options Flow (16/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (9/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 6/9, and Debt/Equity of 8.50x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Organon & Co. (OGN) is a NYSE-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. The company reported revenue of $6.22B for FY 2025. The supply chain is recorded as "NONE."

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Organon & Co. (OGN) reported $6.22B in annual revenue (up from $6.40B in FY2024, -2.9% YoY) and $187.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($6.26B revenue, $1.02B net income) through FY2025, OGN scaled operating cash flow to $700.0M and free cash flow to $538.0M, backed by $12.87B in total assets against $8.63B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B- • RQD 70/100): Strong cash generator (53.3% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 18/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $5.69 – $13.84 52-week range.
🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 19.4x trailing P/E against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context provided is the Health Care classification.

Key Question #1: Can OGN sustain or expand its — operating margin and 24.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $6.22B and free cash flow of $538.0M, how will capital allocation balance growth reinvestment against $8.63B in total debt?
Key Question #3: How sensitive is OGN's 18.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

OGN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Organon & Co. (OGN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OGN Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 22h ago

Organon & Co. (OGN) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Singapore • 1d ago

Organon & Co. (OGN) stock price, news, quote and history

Yahoo Finance Singapore report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Organon & Co stock hits 52-week high at 13.79 USD

Investing.com report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Yahoo Finance report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Q3 revenue fell to $1.57B at Organon (OGN), but profit moved the other way.

Stock Titan report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Yahoo Finance report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Organon stock reaches new 52-week high at USD 13.83

ad-hoc-news.de report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

Organon & Co. (OGN) Holds at $13.75 as Shares Consolidate Between Key Levels - Bear Flag

https://www.dars.gov.et/ report covering Organon & Co. (OGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OGN Bull vs. Bear Conversation Board — What's Your Call at $13.82?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OGN 🐻 33% BEARISH CONVICTION

AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $17.30 (+25.0%)

📌 Pinned Debate

Per the RQD rating, the fundamental cash engine scores 18 of 20 on ROIC of 24.9% and an FCF yield of 14.83%.

Don't sleep on OGN's setup in Health Care. Per the RQD rating, the fundamental cash engine scores 18 of 20 on ROIC of 24.9% and an FCF yield of 14.83%.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (70/100) backs up the fundamental quality.

VolSurface_Trader 🐂 BULL

@ForensicBear Shorting a 16/20 institutional whale-flow stock at $13.84 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $11.07 (-20.0%)

Spot @ $13.84

Net income fell from $1.02B in FY 2023 to $187.0M in FY 2025 while debt stood at $8.63B.

I respect the product at Organon & Co., but the stock at $13.84 is a different story. Net income fell from $1.02B in FY 2023 to $187.0M in FY 2025 while debt stood at $8.63B.. FCF yield is 14.83% and RQD sits at 70/100 (B-) — why pay up here when you can wait for next quarter's numbers?